• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自体骨髓移植中粒细胞集落刺激因子预处理的外周血祖细胞:影响骨髓植入的参数

G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.

作者信息

Bolwell B J, Fishleder A, Andresen S W, Lichtin A E, Koo A, Yanssens T, Burwell R, Baucco P, Green R

机构信息

Department of Hematology/Oncology, Cleveland Clinic Foundation, OH 44195.

出版信息

Bone Marrow Transplant. 1993 Dec;12(6):609-14.

PMID:7511016
Abstract

G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 micrograms/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 micrograms/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 10(9)/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 10(9)/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

粒细胞集落刺激因子(G-CSF)和粒细胞-巨噬细胞集落刺激因子(GM-CSF)可提高自体骨髓移植(ABMT)中中性粒细胞的植入率,且对血小板植入无显著影响。外周血祖细胞(PBPC)可能会提高中性粒细胞和血小板的植入率。我们对49例接受ABMT的患者采用一个疗程的G-CSF治疗以获取PBPC,并在移植后将这些细胞与G-CSF一起输注,试图确定可能与增强骨髓植入相关的因素。对49例患有霍奇金病、非霍奇金淋巴瘤或乳腺癌且接受未净化ABMT的患者进行了研究。G-CSF启动治疗包括门诊8天疗程,剂量为5微克/千克/天,随后进行三次白细胞分离术(在第5、7和8天)以采集PBPC。患者随后接受化疗性骨髓移植预处理方案,接着输注PBPC、自体骨髓并重新使用G-CSF(16微克/千克/天)。骨髓植入迅速。达到0.5×10⁹/L中性粒细胞的中位时间为10天,而接受相同预处理方案的历史骨髓移植对照患者群体为19天(p = 0.001)。达到血小板计数20×10⁹/L的时间为16天,而历史对照为22天(p = 0.001)。所有患者在+14天时均出现中性粒细胞植入。骨髓植入与输注的CD34⁺细胞总数以及输注的单核细胞总数相关,但与输注的CD34⁺/CD33⁻细胞总数无关。采集的全血体积量与总单核细胞产量显著相关。既往接受放射治疗与祖细胞产量呈负相关。(摘要截短于250词)

相似文献

1
G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.自体骨髓移植中粒细胞集落刺激因子预处理的外周血祖细胞:影响骨髓植入的参数
Bone Marrow Transplant. 1993 Dec;12(6):609-14.
2
Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.粒细胞集落刺激因子(G-CSF)与粒细胞-巨噬细胞集落刺激因子(GM-CSF)在动员外周血祖细胞及促进自体骨髓移植后骨髓恢复方面的比较。
Bone Marrow Transplant. 1994 Dec;14(6):913-8.
3
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.自体骨髓移植后,人骨髓髓系祖细胞对单独使用粒细胞集落刺激因子以及联合白细胞介素-3进行体内治疗的增殖反应。
Exp Hematol. 1995 Dec;23(14):1520-6.
4
Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.大剂量治疗及自体外周血祖细胞移植后影响造血恢复的因素:单中心经验
Haematologica. 1998 Apr;83(4):329-37.
5
Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.自体非格司亭(粒细胞集落刺激因子)动员的外周血祖细胞用于恢复淋巴恶性肿瘤大剂量化疗后造血功能的II期研究。
Bone Marrow Transplant. 1994 Jul;14(1):105-11.
6
Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.细胞因子预处理的骨髓干细胞与外周血干细胞用于自体移植:GM-CSF与G-CSF的随机对照比较
Biol Blood Marrow Transplant. 1997 Oct;3(4):217-23.
7
Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.使用非控速冷冻保存进行外周血干细胞移植:与自体骨髓移植的比较。
Exp Hematol. 1994 Mar;22(3):290-4.
8
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.影响淋巴瘤患者外周血祖细胞动员的因素。
Clin Cancer Res. 1998 Feb;4(2):311-6.
9
Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.采用化疗加重组人粒细胞集落刺激因子动员的血液干细胞进行清髓性预处理治疗后成功进行自体移植。
Exp Hematol. 1993 Apr;21(4):508-14.
10
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.外周血祖细胞与骨髓作为非霍奇金淋巴瘤和霍奇金病患者大剂量化疗造血支持的随机试验:临床与分子分析
Bone Marrow Transplant. 1999 Sep;24(5):473-81. doi: 10.1038/sj.bmt.1701941.

引用本文的文献

1
Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience.使用粒细胞集落刺激因子动员造血祖细胞用于血液系统恶性肿瘤的自体移植:单中心经验
Rev Bras Hematol Hemoter. 2011;33(6):410-6. doi: 10.5581/1516-8484.20110115.
2
A comparative review of colony-stimulating factors.集落刺激因子的比较综述
Drugs. 1997 Nov;54(5):709-29. doi: 10.2165/00003495-199754050-00004.
3
Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters.
粒细胞巨噬细胞集落刺激因子在中性粒细胞恢复方面与医疗保健参数相关的临床作用。
Med Oncol. 1996 Sep;13(3):177-84. doi: 10.1007/BF02990845.
4
Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF.使用化疗和粒细胞巨噬细胞集落刺激因子(GM-CSF)动员的外周血祖细胞(PBPC)进行大剂量强化治疗后血液学恢复情况的改善。
Ann Hematol. 1994 Dec;69(6):297-302. doi: 10.1007/BF01696558.
5
Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.非格司亭。其药理学特性及对中性粒细胞减少症治疗效果的综述。
Drugs. 1994 Nov;48(5):731-60. doi: 10.2165/00003495-199448050-00007.